Skip to main content
Top
Published in: Thyroid Research 1/2019

Open Access 01-12-2019 | Metastasis | Research

Semi-quantitative assessment of diffuse hepatic uptake seen in I-131 scans – an indicator of functioning thyroid tissue and disease burden in differentiated thyroid cancer

Authors: Prasanta K. Pradhan, Suruchi Jain, Madhusudhanan Ponnuswamy, Amitabh Arya, Manish Ora

Published in: Thyroid Research | Issue 1/2019

Login to get access

Abstract

Background

To semi-quantitatively analyze liver uptake of I-131 in diagnostic and post-therapy scans by calculating hepatic to thigh ratios (HTR) and evaluate its clinical significance in management of differentiated thyroid cancer.

Method

Two hundred forty-nine patients were included in the study. Hepatic to thigh ratio (HTR) of counts were calculated for 249 diagnostic and 104 post-therapy scans. Patients were divided into six study groups based on their disease status:1-Serum thyroglobulin (serum Tg) negative (serum Tg ≤ 4 ng/dl) and scan negative; 2-Thyroid remnant only; 3-Thyroid remnant and lymph node metastasis; 4- Tg positive (serum Tg > 4 ng/dl) and scan negative; 5-Bone or/and lung metastasis, and 6-Only lymph node metastasis. Comparison of HTR between these groups was done using one-way ANOVA test. Correlation of HTR with serum Tg, serum thyroid stimulating hormone (TSH), anti-thyroglobulin antibody (ATg) titer and therapeutic dose of I-131 was also assessed.

Results

Comparison of HTR between different study groups (1 to 6) showed significant difference in HTR (p = .001). Study group 5 (bone or/and lung metastasis) showed significantly higher mean HTR compared to other groups (p = 0.001). There was only a weak correlation between serum Tg and HTR (r = 0.395). Dose of I-131 administered also had a weak correlation with HTR (r = 0.207).

Conclusion

HTR has good correlation with functional status of tumor cells, while it has weak correlation to therapeutic dose of I-131 administered and serum Tg. Increased HTR predicts significant disease burden in the form of distant bone and lung metastasis and may potentially be used as a second prognostic factor apart from serum Tg.
Literature
1.
go back to reference McDougall IR. Whole-body scintigraphy with radioiodine-131. A comprehensive list of false positives with some examples. ClinNucl Med. 1995;20:869–75. McDougall IR. Whole-body scintigraphy with radioiodine-131. A comprehensive list of false positives with some examples. ClinNucl Med. 1995;20:869–75.
2.
go back to reference Carlisle MR, Lu C, McDougall IR. The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun. 2003;24(6):715–35.CrossRef Carlisle MR, Lu C, McDougall IR. The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun. 2003;24(6):715–35.CrossRef
3.
go back to reference Wu SY, Brown T, Milne N, et al. Lodine-131 total body scan extrathyroidal uptake of radioiodine. SeminNucl Med. 1986;16:82–4. Wu SY, Brown T, Milne N, et al. Lodine-131 total body scan extrathyroidal uptake of radioiodine. SeminNucl Med. 1986;16:82–4.
4.
go back to reference Maayan ML, Eisenberg J, Lopez EM, Rothschild MA. Hepatic visualization after iodine-131 in patients with thyroid carcinoma. N Engl J Med. 1986;295:1258–70. Maayan ML, Eisenberg J, Lopez EM, Rothschild MA. Hepatic visualization after iodine-131 in patients with thyroid carcinoma. N Engl J Med. 1986;295:1258–70.
5.
go back to reference Rosenbaum RC, Johnston GS, Valente WA. Frequency of hepatic visualization during I-131 imaging for metastatic thyroid carcinoma. Clin Nucl Med. 1988;13:657–60.CrossRef Rosenbaum RC, Johnston GS, Valente WA. Frequency of hepatic visualization during I-131 imaging for metastatic thyroid carcinoma. Clin Nucl Med. 1988;13:657–60.CrossRef
6.
go back to reference Chung JK, Lee YJ, Jeong JM, et al. Clinical significance of hepatic visualization on iodine-131 whole body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38(8):1191–5.PubMed Chung JK, Lee YJ, Jeong JM, et al. Clinical significance of hepatic visualization on iodine-131 whole body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38(8):1191–5.PubMed
7.
go back to reference Tatar FA, Morita E, Ituarte PH, et al. Association between residual thyroid carcinoma and diffuse hepatic uptake of I-131 following radioiodine ablation in postoperative total thyroidectomy patients. World J Surg. 2001;25:718–22.CrossRef Tatar FA, Morita E, Ituarte PH, et al. Association between residual thyroid carcinoma and diffuse hepatic uptake of I-131 following radioiodine ablation in postoperative total thyroidectomy patients. World J Surg. 2001;25:718–22.CrossRef
8.
go back to reference Blum M. Hepatic visualization after 131-I in patients with thyroid carcinoma. N Engl J Med. 1977;296:634.PubMed Blum M. Hepatic visualization after 131-I in patients with thyroid carcinoma. N Engl J Med. 1977;296:634.PubMed
9.
go back to reference Ziessman HA, Bahar H, Fahey FH, Dubiansky V. Hepatic visualization of iodine-131 whole-body thyroid cancer scans. J Nucl Med. 1987 Sep;28(9):1408–11.PubMed Ziessman HA, Bahar H, Fahey FH, Dubiansky V. Hepatic visualization of iodine-131 whole-body thyroid cancer scans. J Nucl Med. 1987 Sep;28(9):1408–11.PubMed
10.
go back to reference Mazzaferri EL. Treatment of carcinoma of follicular epithelium. In: The thyroid: a fundamental and clinical text. 5th ed. Philadelphia: JB Lippincott; 1986. p. 1329–46. Mazzaferri EL. Treatment of carcinoma of follicular epithelium. In: The thyroid: a fundamental and clinical text. 5th ed. Philadelphia: JB Lippincott; 1986. p. 1329–46.
11.
go back to reference Jun S, Lee JJ, Park SH, et al. Prediction of treatment response to 131I therapy by diffuse hepatic uptake intensity on post-therapy whole-body scan in patients with distant metastases of differentiated thyroid cancer. Ann Nucl Med. 2015;29(7):603–12.CrossRef Jun S, Lee JJ, Park SH, et al. Prediction of treatment response to 131I therapy by diffuse hepatic uptake intensity on post-therapy whole-body scan in patients with distant metastases of differentiated thyroid cancer. Ann Nucl Med. 2015;29(7):603–12.CrossRef
12.
go back to reference Hays M, McDougall IR. Circulating 131I thyroxine and thyroid cancer. Thyroid. 1994;4:195–8.CrossRef Hays M, McDougall IR. Circulating 131I thyroxine and thyroid cancer. Thyroid. 1994;4:195–8.CrossRef
13.
go back to reference Albert DM, Puliafito CA. Hepatic visualization after iodine-131 in patients with thyroid carcinoma. N Engl J Med. 1977;296:634.PubMed Albert DM, Puliafito CA. Hepatic visualization after iodine-131 in patients with thyroid carcinoma. N Engl J Med. 1977;296:634.PubMed
14.
go back to reference Omur O, et al. Clinical implications of diffuse hepatic uptake observed in Postablative and post-therapeutic 131I scans. Clin Nucl Med. 2009;34:1.CrossRef Omur O, et al. Clinical implications of diffuse hepatic uptake observed in Postablative and post-therapeutic 131I scans. Clin Nucl Med. 2009;34:1.CrossRef
15.
go back to reference Lee JW, Lee SM, Choi J. Clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed (131)I scan in differentiated thyroid cancer: a preliminary report. Ann Nucl Med. 2015;29:190–7.CrossRef Lee JW, Lee SM, Choi J. Clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed (131)I scan in differentiated thyroid cancer: a preliminary report. Ann Nucl Med. 2015;29:190–7.CrossRef
16.
go back to reference Nakayama M, Okizaki A, Sakaguchi M, Ishitoya S, Uno T, Sato J, Takahashi KA. Quantitative evaluation of hepatic uptake on I-131 whole-body scintigraphy for Postablative therapy of thyroid carcinoma. Medicine. 2015;94(28):e1191.CrossRef Nakayama M, Okizaki A, Sakaguchi M, Ishitoya S, Uno T, Sato J, Takahashi KA. Quantitative evaluation of hepatic uptake on I-131 whole-body scintigraphy for Postablative therapy of thyroid carcinoma. Medicine. 2015;94(28):e1191.CrossRef
17.
go back to reference Hammersley PA, Al-Saadi A, Chittenden S, Flux GD, McCready VR, Harmer CL, et al. Value of protein-bound radioactive iodine measurements in the management of differentiated thyroid cancer treated with 131I. Br J Radiol. 2001;74:429–33.CrossRef Hammersley PA, Al-Saadi A, Chittenden S, Flux GD, McCready VR, Harmer CL, et al. Value of protein-bound radioactive iodine measurements in the management of differentiated thyroid cancer treated with 131I. Br J Radiol. 2001;74:429–33.CrossRef
18.
go back to reference Schober B, Cohen P, Lyster D, Charron M, Lentie B. Diffuse liver uptake of iodine-131. J Nucl Med. 1990;31(9):1575–6.PubMed Schober B, Cohen P, Lyster D, Charron M, Lentie B. Diffuse liver uptake of iodine-131. J Nucl Med. 1990;31(9):1575–6.PubMed
19.
go back to reference Schlumberger M. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306.CrossRef Schlumberger M. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306.CrossRef
Metadata
Title
Semi-quantitative assessment of diffuse hepatic uptake seen in I-131 scans – an indicator of functioning thyroid tissue and disease burden in differentiated thyroid cancer
Authors
Prasanta K. Pradhan
Suruchi Jain
Madhusudhanan Ponnuswamy
Amitabh Arya
Manish Ora
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Thyroid Research / Issue 1/2019
Electronic ISSN: 1756-6614
DOI
https://doi.org/10.1186/s13044-019-0065-1

Other articles of this Issue 1/2019

Thyroid Research 1/2019 Go to the issue